Momentum Group Limited applied to merge with African Life Health (Pty) Ltd on 2 September 2005. The Competition Commission investigated and recommended unconditional approval on 9 November 2005. The Competition Tribunal approved the merger on 12 December 2005 but imposed conditions requiring persons holding dual directorships on both Momentum Group and Discovery Group boards to resign from one board within one month, and prohibiting future cross-directorships while FirstRand Limited controlled both groups. Both Momentum and Discovery were controlled by FirstRand Limited, which held approximately 65.6% of Discovery Holdings. Post-merger, the combined entity would command 34.62% of the medical scheme administration market. FirstRand operated a policy of maintaining vigorous competition between its subsidiaries, with an "owner manager" ethos allowing operational autonomy. The cross-directorships existed at holding company level (specifically Mr. Lauritz Lanser Dippenaar and Mr. Johan Petrus Burger, FirstRand's CEO and CFO) for corporate governance purposes, not operational coordination. The applicants sought review and appealed the conditions, arguing they were imposed without proper evidential basis or opportunity to be heard on their commercial effects.
The Competition Appeal Court set aside the conditions imposed by the Competition Tribunal and approved the merger unconditionally on 2 February 2006. Both the review application and the appeal succeeded.
The binding legal principles established are: (1) The Competition Tribunal has jurisdiction to impose conditions on mergers even where no party disputes unconditional approval, as it is not a mere rubber stamp but must exercise independent judgment under sections 16 and 27 of the Competition Act 89 of 1998; (2) A 'lis' or dispute between parties is not a prerequisite for the Tribunal to exercise its powers, given the public nature of its functions and its inquisitorial powers under the Act; (3) However, to ensure procedural fairness, the Tribunal must afford affected parties an opportunity to respond by placing evidence and/or argument before it regarding conditions it may consider imposing; (4) Conditions imposed on merger approval must be supported by proper evidence of a substantial lessening of competition in the relevant market as required by section 12A of the Act; (5) Cross-directorships at holding company level that serve legitimate corporate governance purposes (monitoring, accountability, group policy implementation) do not per se create anti-competitive coordination risks, particularly where uncontested evidence demonstrates operational independence and competitive rivalry between subsidiaries; (6) Common ownership through a holding company does not automatically justify aggregating market shares or finding coordination risk where evidence establishes genuine internal competition and commercial reasons for maintaining separate competitive entities; (7) Conditions must be appropriately framed and proportionate to the actual competition concerns identified, supported by evidence rather than theoretical possibilities.
The Court made several non-binding observations: (1) It noted uncertainty about whether individual directors affected by the Tribunal's order should have been joined from the outset, but found it unnecessary to decide as they were willing to submit to the court's jurisdiction; (2) The Court observed that the conditions imposed were too broadly framed, covering services beyond medical administration where no competition concerns arose; (3) The Court commented that the conditions provided no real safeguard against information sharing as they didn't restrict non-directors from attending board meetings; (4) Malan AJA noted approvingly the practice of having holding company executives (CEO and CFO) serve on subsidiary boards as consistent with good corporate governance and the spirit of the King Report on Corporate Governance for South Africa - 2002; (5) The Court distinguished merger cases from restrictive practices cases, noting that in the former the Tribunal must exercise independent discretion rather than simply endorsing consent agreements (citing Coleus Packaging); (6) The judgment observed that FirstRand could theoretically consolidate Momentum and Discovery if it wished, but there were sound commercial and emotional reasons (including founders' continued involvement) why it preferred maintaining competition between them; (7) The Court noted that finance houses like FirstRand are principally concerned with investment returns and need consolidated information for proper group management, which requires cross-representation at board level.
This case establishes important principles regarding the Competition Tribunal's powers and procedures in merger control. It confirms that while the Tribunal has broad inquisitorial powers and is not bound by the Commission's recommendations or parties' consent, it must provide procedural fairness by affording affected parties opportunity to address proposed conditions. The judgment emphasizes that conditions must be supported by proper evidence of anti-competitive effects, not mere theoretical possibilities. It recognizes that cross-directorships at holding company level serving legitimate corporate governance functions do not automatically create collusion risks, particularly where evidence demonstrates operational independence and competitive rivalry between subsidiaries. The case is significant for establishing that common ownership through a holding company does not automatically justify aggregating market shares or imposing structural remedies where evidence shows genuine internal competition. It sets standards for evidentiary burden when imposing merger conditions and reinforces that merger control must be based on actual competitive effects in the relevant market, not speculative concerns. The judgment also provides guidance on appropriate corporate governance structures in group companies and distinguishes between holding company oversight and operational coordination.